|
Gene: TPD52L2 |
Gene summary for TPD52L2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TPD52L2 | Gene ID | 7165 |
Gene name | TPD52 like 2 | |
Gene Alias | D54 | |
Cytomap | 20q13.33 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | O43399 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7165 | TPD52L2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.33e-02 | 6.93e-02 | 0.0155 |
7165 | TPD52L2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.45e-03 | 2.40e-01 | -0.1808 |
7165 | TPD52L2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.08e-04 | 2.58e-01 | -0.0811 |
7165 | TPD52L2 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.74e-02 | 1.81e-01 | -0.1088 |
7165 | TPD52L2 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.75e-16 | 3.02e-01 | -0.1954 |
7165 | TPD52L2 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.62e-09 | 3.52e-01 | -0.1526 |
7165 | TPD52L2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.05e-08 | 2.81e-01 | -0.1464 |
7165 | TPD52L2 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.42e-02 | 1.47e-01 | -0.1001 |
7165 | TPD52L2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.34e-11 | 3.70e-01 | -0.059 |
7165 | TPD52L2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.31e-06 | 1.95e-01 | 0.096 |
7165 | TPD52L2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.35e-03 | 2.36e-01 | 0.281 |
7165 | TPD52L2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.44e-32 | 8.51e-01 | 0.3859 |
7165 | TPD52L2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.02e-09 | 4.83e-01 | 0.2585 |
7165 | TPD52L2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.43e-07 | 3.19e-01 | 0.3005 |
7165 | TPD52L2 | A001-C-007 | Human | Colorectum | CRC | 2.44e-02 | 3.14e-01 | 0.1899 |
7165 | TPD52L2 | CRC-1-8810 | Human | Colorectum | CRC | 3.46e-02 | 2.22e-01 | 0.6257 |
7165 | TPD52L2 | CRC-3-11773 | Human | Colorectum | CRC | 1.89e-10 | 5.24e-01 | 0.2564 |
7165 | TPD52L2 | LZE4T | Human | Esophagus | ESCC | 6.24e-17 | 5.32e-01 | 0.0811 |
7165 | TPD52L2 | LZE7T | Human | Esophagus | ESCC | 3.70e-07 | 5.00e-01 | 0.0667 |
7165 | TPD52L2 | LZE8T | Human | Esophagus | ESCC | 9.49e-08 | 3.69e-01 | 0.067 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TPD52L2 | SNV | Missense_Mutation | rs753959135 | c.251N>T | p.Ser84Phe | p.S84F | O43399 | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
TPD52L2 | SNV | Missense_Mutation | novel | c.556N>C | p.Thr186Pro | p.T186P | O43399 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
TPD52L2 | SNV | Missense_Mutation | novel | c.260N>A | p.Gly87Glu | p.G87E | O43399 | protein_coding | tolerated(0.66) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TPD52L2 | SNV | Missense_Mutation | c.354N>C | p.Glu118Asp | p.E118D | O43399 | protein_coding | tolerated(0.73) | benign(0.039) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
TPD52L2 | SNV | Missense_Mutation | c.397C>T | p.Leu133Phe | p.L133F | O43399 | protein_coding | deleterious(0.03) | benign(0.398) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TPD52L2 | SNV | Missense_Mutation | rs759116051 | c.56N>T | p.Ser19Phe | p.S19F | O43399 | protein_coding | deleterious(0.02) | possibly_damaging(0.892) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
TPD52L2 | SNV | Missense_Mutation | novel | c.53N>C | p.Leu18Pro | p.L18P | O43399 | protein_coding | deleterious(0.04) | benign(0.118) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TPD52L2 | SNV | Missense_Mutation | c.532A>G | p.Met178Val | p.M178V | O43399 | protein_coding | tolerated(0.11) | probably_damaging(0.989) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
TPD52L2 | SNV | Missense_Mutation | novel | c.341N>A | p.Gly114Glu | p.G114E | O43399 | protein_coding | tolerated_low_confidence(0.18) | benign(0.037) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
TPD52L2 | SNV | Missense_Mutation | rs769017990 | c.679N>A | p.Ala227Thr | p.A227T | O43399 | protein_coding | tolerated_low_confidence(0.4) | benign(0.001) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |